Wanda (or ‘the Company’), the intelligent platform for Remote Patient Monitoring (‘RPM’) and Virtual Care, is excited to announce that it has entered into a strategic partnership with the COPD Foundation, a leading nonprofit organisation dedicated to improving the lives of individuals affected by chronic lung diseases, including Chronic Obstructive Pulmonary Disease (‘COPD’), bronchiectasis and NTM lung disease. COPD is a disease which affects more than 30 million Americans and is the third leading cause of death worldwide.
Wanda, backed by London-based EMV Capital plc and other private investors, helps to empower healthcare providers and payers with early detection of exacerbations in patients with acute, chronic and specialty diseases, helping them speed interventions, prevent adverse events and improve patient adherence. Working hand-in-hand with organisations such as the COPD Foundation allows Wanda to leverage expert insights and resources, ensuring that their platform delivers targeted solutions that, in this case, meets the specific needs of patients with respiratory conditions.
This collaborative relationship will open the doors to some of the world’s leading doctors and medical experts in lung health, enabling the Company to leverage their expertise to continue to hone their innovative platform and proprietary AI and Machine Learning capabilities. The partnership will also provide marketing and advertising opportunities; including space in a peer-reviewed Medical Journal.
The global connected healthcare market size is projected to grow from approximately US$51.59 billion in 2021 to approximately US$297.95 billion in 2028[1], with market demand exploding across all regions, particularly in North America, Europe and Asia Pacific. This collaboration will give Wanda access to the COPD Foundation’s own partner network, to support the Company’s business development efforts.
“This partnership marks a significant milestone in our mission to usher in the new wave of digital care and demonstrates that we are a trusted technology partner,” said Tom Smith, Chief Executive Officer of Wanda. “By collaborating with these organisations we are able to increase our reach, but also ensure that our platform is informed by some of the most important medical minds working in respiratory health. This collaboration will facilitate our access to a wider network of hospitals and clinics, which will also support our go to market strategy. This synergy will allow for effective marketing and advertising opportunities, as well as the sharing of crucial information that can lead to improved treatment protocols and patient education.”
“At the COPD Foundation, we are dedicated to collaborating on innovative initiatives that empower individuals living with chronic lung diseases to better manage their health,” said Jean Wright, M.D., MBA, CEO of the COPD Foundation. “While there is no cure for COPD yet, effective disease management can make a significant difference in symptom relief and quality of life. By collaborating with Wanda, we aim to raise awareness about RPM technologies and how it can offer timely insights into health changes while supporting proactive care for those affected by chronic lung diseases, including COPD.”
[1] Fortune Business Insights
